Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Ventures L.P. 5Am sold 10,494 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $7.00, for a total transaction of $73,458.00. Following the completion of the sale, the insider directly owned 2,836,098 shares in the company, valued at approximately $19,852,686. This represents a 0.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Entrada Therapeutics Trading Up 1.2%

Shares of TRDA stock traded up $0.08 during trading hours on Monday, reaching $6.95. 411,770 shares of the stock were exchanged, compared to its average volume of 464,800. The firm has a market capitalization of $270.63 million, a price-to-earnings ratio of -1.76 and a beta of -0.26. Entrada Therapeutics, Inc. has a 12-month low of $4.93 and a 12-month high of $16.45. The company’s 50-day moving average price is $6.86 and its 200-day moving average price is $9.68.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The firm had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. On average, sell-side analysts expect that Entrada Therapeutics, Inc. will post -4.07 EPS for the current year.

Institutional Investors Weigh In On Entrada Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TRDA. Baker BROS. Advisors LP grew its holdings in Entrada Therapeutics by 4.3% during the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after acquiring an additional 206,911 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Entrada Therapeutics by 735.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 133,878 shares of the company’s stock valued at $776,000 after purchasing an additional 117,844 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Entrada Therapeutics by 9.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after purchasing an additional 1,560 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Entrada Therapeutics in the 2nd quarter worth approximately $19,013,000. Finally, Deutsche Bank AG purchased a new stake in shares of Entrada Therapeutics in the 2nd quarter worth approximately $195,000. 86.39% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on TRDA. Roth Capital set a $10.00 price objective on Entrada Therapeutics in a report on Friday, May 8th. Guggenheim decreased their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Weiss Ratings lowered shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. Finally, HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $17.50.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.